Ferring would like to use cookies to better understand your use of this website and improve your experience while navigating it. Please accept our use of cookies in accordance with our privacy policy. 

Accept / Decline


FERRING Canada announces the launch of CORTIMENT® MMX (budesonide) a new treatment for ulcerative colitis

TORONTOJuly 28, 2016 /CNW/ - Ferring Canada, a subsidiary of Ferring Pharmaceuticals announced today the availability inCanada of CORTIMENT® MMX (budesonide delayed and extended release tablets) treatment for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC), one of the two most common types of inflammatory bowel disease (IBD). Canadahas among the highest reported rates of IBD in the world. Ulcerative colitis is a condition that can be very debilitating and significantly compromise quality of life. Approximately 104,000 Canadians are living with UC.

Click here to read more

See more Newsroom


Ferring Canada
200 Yorkland Boulevard, Suite 500
Toronto, Ontario, M2J 5C1 

Tel:  +1 416 490 0121 or +1 800 263 4057
Fax: 416 493 1692